Grant RDF
pages:- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- more...
- A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1, GT2, and GT4 Infection
- A Phase II, Twelve-week, Double-Blind and Placebo-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of CP 448, 187 (1.5 mg and 3.0 mg) in Subjects with Obsessive Compulsive Disorder
- A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK- 5172 and MK-8742 ± Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis and Child-Pugh (CP)-B Hepatic Insufficiency
- A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Mk-5172 and Mk-8742
- A Phase II/III Ran...Comparing Sirolimus Plus Prednicons, Sirolimus/Extracoporeal Photopheresis Plus Prednisone; and Sir
- A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Mk-5172 &
- A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Disease
- A Phase II/III Randomized Study of Cdx-110 With Radiation & Temozolomide in Patients With Newly Diagnosed Glioblastoma..
- A Phase II/III, Double-Blind, Randomized, Controlled, Multiceenter Study to Assess the Safety and Cardiovascular Effects
- A Phase Iia Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6-Hour Intravenous
- A Phase Iia Study of the Safety,Tolerability and Hemodynamiceffects of a Continuous 6-Hour Intravenous Infusion of Cxl..
- A Phase Iia, 3 Strata Dose Defining Study Evaluating the Hemodynamic Effects Safety and Tolerability of Cxl-1020 in Pat
- A Phase Iia, 3 Strata Dose-Defining Study Evaluating the Hemodynamic Effects, Safety and Tolerability of Cxl-1020 . .
- A Phase Iia, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety and Effect on ....
- A Phase Iib Clinical Trial to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine (Nm283) in ...
- A Phase IIb Clinical Trial to Evaluate the Combination of Pegylated Interferon Alfa plus Valopicitabine (NM283) in Treatment-Naïve Patients with Chronic Hepatitis C
- A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Ulcerative Colitis (UC)
- A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subjects with Moderate to Severe Crohn’s Disease
- A Phase Iib, Randomized, Multicenter, Open-Label, Concentration-Controlled, Safety Study of Isa247 and Tacrolimus.......
- A Phase III 3 Arm Randomized Double Blind Placebo Controlled Multicenter Study to Investigate the Impact of Diamyd......
- A Phase III Double Blind Randomized Placebo Controlled Study to Evaluate the Effects of Ro4607381 on Cardiovascular.....
- A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of . . .
- A Phase III Multi-Center Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy .
- A Phase III Multicenter Clinical Trial of Analatro (Antivenin Latrodectus (Black Widow) Equine Immune F(Ab2) in Patients
- A Phase III Open-Label Extension Trial of Ecu-Mg-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects..
- A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon
- A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon
- A Phase III Randomized Clinical Trial of Pembrolizumab (Mk-3475) Versus Paclitaxel, Docetaxel or Vinflunine....
- A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavirin (P/R) with Chronic HCV GT1, GT4, GT5, and GT6 Infection
- A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, and GT6 Infection